Literature DB >> 22212172

MRSA eradication in dermatologic outpatients - theory and practice.

Volker Meyer1, Nina Kerk, Alexander Mellmann, Alexander Friedrich, Thomas A Luger, Tobias Goerge.   

Abstract

BACKGROUND: The dissemination of methicillin resistant staphylococcus aureus (MRSA) is an increasing challenge in medical care. Apart from hospital acquired MRSA, there has also been an increase in community acquired and livestock associated MRSA. While the risks of MRSA (e. g. wound infections) and consequences (e. g. rejection of patients) are well known, there are little data on the effectiveness of eradication procedures. PATIENTS AND METHODS: 32 patients with proven MRSA colonization were monitored during eradication for the following aspects: (1) localization of MRSA (swabs from hairline, anterior nares, throat, axillae, groins, perineum, and wounds, if present), (2) presence of eradication-impairing factors, (3) length of time needed for eradication, (4) cost of eradication, (5) molecular fingerprint and risk assessment (spa-types).
RESULTS: We describe the successful eradication of MRSA in all 32 patients. Most positive nasal swabs were obtained from the anterior nares and the throat and only rarely from the hairline or axillae. The greater the number of positive swabs, the more time was needed for eradication. In most patients (37.5%), eradication with topical antiseptics was successful. The average time for eradication was 12.97 (± 7.6) days. Twelve patients required systemic antibiotic therapy. Treatment costs associated with the use of systemic antibiotics were significantly higher. The most frequent spa types were t032 and t003.
CONCLUSIONS: We report successful MRSA eradication in outpatients. Systemic antibiotics are unnecessary in the majority of patients. A combined anti-MRSA strategy for inpatients and outpatients is recommended.
© The Authors • Journal compilation © Blackwell Verlag GmbH, Berlin.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22212172     DOI: 10.1111/j.1610-0387.2011.07861.x

Source DB:  PubMed          Journal:  J Dtsch Dermatol Ges        ISSN: 1610-0379            Impact factor:   5.584


  6 in total

1.  In vitro susceptibility of methicillin-resistant and methicillin-susceptible strains of Staphylococcus aureus to two different cold atmospheric plasma sources.

Authors:  Matthias Napp; Georg Daeschlein; Sebastian von Podewils; Peter Hinz; Steffen Emmert; Hermann Haase; Romy Spitzmueller; Denis Gümbel; Richard Kasch; Michael Jünger
Journal:  Infection       Date:  2016-03-07       Impact factor: 3.553

2.  MRSA prevalence rates detected in a tertiary care hospital in Austria and successful treatment of MRSA positive patients applying a decontamination regime with octenidine.

Authors:  G Pichler; C Pux; R Babeluk; B Hermann; E Stoiser; A De Campo; A Grisold; I Zollner-Schwetz; R Krause; W Schippinger
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-08-28       Impact factor: 3.267

Review 3.  Management of Dermatologic Complications of Lung Cancer Therapies.

Authors:  Silvina B Pugliese; Joel W Neal; Bernice Y Kwong
Journal:  Curr Treat Options Oncol       Date:  2015-10

4.  Efficacy of the decolonization of methicillin-resistant Staphylococcus aureus carriers in clinical practice.

Authors:  N Sai; C Laurent; H Strale; O Denis; B Byl
Journal:  Antimicrob Resist Infect Control       Date:  2015-12-18       Impact factor: 4.887

5.  Integrated MRSA-Management (IMM) with prolonged decolonization treatment after hospital discharge is effective: a single centre, non-randomised open-label trial.

Authors:  Bernhard Jahn; Trudy M Wassenaar; Annemarie Stroh
Journal:  Antimicrob Resist Infect Control       Date:  2016-06-14       Impact factor: 4.887

6.  Care for MRSA carriers in the outpatient sector: a survey among MRSA carriers and physicians in two regions in Germany.

Authors:  Heike Raupach-Rosin; Nicole Rübsamen; Sebastian Szkopek; Oliver Schmalz; André Karch; Rafael Mikolajczyk; Stefanie Castell
Journal:  BMC Infect Dis       Date:  2016-04-26       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.